<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853072</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-067</org_study_id>
    <nct_id>NCT01853072</nct_id>
  </id_info>
  <brief_title>Nepafenac Once Daily for Macular Edema - Study 1</brief_title>
  <official_title>Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension,
      0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among
      diabetic subjects following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects with BCVA improvement of ≥ 15 letters from preoperative baseline to Day 14 and maintained through Day 90</measure>
    <time_frame>Baseline, up to Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who develop macular edema (defined as ≥ 30% increase from pre-operative baseline in central subfield macular thickness) within 90 days following cataract surgery</measure>
    <time_frame>Baseline, up to Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured with Spectral Domain Ocular Coherence Tomography (SD-OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BCVA improvement of ≥ 15 letters from preoperative baseline to Day 90</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BCVA improvement of ≥ 15 letters from preoperative baseline to Day 60</measure>
    <time_frame>Baseline, Day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Non-Proliferative Diabetic Retinopathy</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac Ophthalmic Suspension, 0.3%</intervention_name>
    <arm_group_label>Nepafenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nepafenac vehicle</intervention_name>
    <description>Inactive ingredients used as placebo comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate ophthalmic suspension</intervention_name>
    <description>1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks</description>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Omnipred™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned cataract extraction by phacoemulsification with implantation of a posterior
             chamber intraocular lens;

          -  History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR)
             (mild, moderate, or severe) in the study eye;

          -  Best corrected visual acuity (BCVA) of 73 letters or worse in the study eye with
             expectation of improvement after surgery;

          -  Understand and sign an informed consent document;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pre-existing macular edema in the study eye;

          -  History in the study eye of retinal detachment, wet age-related macular degeneration,
             chronic or recurrent inflammatory eye disease, or prior procedures;

          -  Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study
             visit or through study exit;

          -  Planned multiple procedures for the study eye during the cataract/intraocular lens;

          -  Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs
             (NSAIDs) and steroids, as specified in protocol.

          -  Participation in any other clinical study within 30 days of the screening visit;

          -  Females of childbearing potential who are breast feeding, have a positive urine
             pregnancy test at screening, are not willing to undergo a urine pregnancy test upon
             entering or exiting the study, intend to become pregnant during the study, or do not
             agree to use adequate birth control methods for the duration of the study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijit Narvekar, MS, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center at 1-888-451-3937 for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Type I</keyword>
  <keyword>Diabetes Type II</keyword>
  <keyword>non-proliferative diabetic retinopathy</keyword>
  <keyword>macular edema</keyword>
  <keyword>Cataract</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
